What is the antihypertensive of choice for a 30-year-old Asian female with undiagnosed hypertension and an estimated glomerular filtration rate of 46 mL/min/1.73 m²?

ACE Inhibitor or ARB is the Antihypertensive of Choice

For this 30-year-old Asian female with newly diagnosed hypertension and eGFR 46 mL/min/1.73 m² (CKD stage G3a), start a renin-angiotensin system inhibitor (ACE inhibitor or ARB) as first-line therapy. 1

Rationale and Clinical Approach

Why RAS Inhibition is Essential

This patient has CKD stage G3a (eGFR 46), which automatically makes her a candidate for RAS inhibition regardless of albuminuria status. The KDIGO 2021 guidelines provide clear direction:

• If albuminuria is severely increased (A3, ≥300 mg/g): RAS inhibitor is strongly recommended (1B evidence) 1
• If albuminuria is moderately increased (A2, 30-300 mg/g): RAS inhibitor is suggested (2C evidence) 1
• If no albuminuria is present (A1, <30 mg/g): It remains reasonable to use RAS inhibitor in CKD patients with hypertension 1

The 2025 AHA/ACC guidelines reinforce this, recommending ACE inhibitor or ARB in adults with diabetes and hypertension when eGFR <60 mL/min/1.73 m² 2

Critical First Step: Check Albuminuria

Before initiating therapy, obtain a urine albumin-to-creatinine ratio to properly stage her CKD and guide intensity of treatment. This is essential for:

• Determining strength of RAS inhibitor indication
• Establishing baseline for monitoring kidney disease progression
• Assessing cardiovascular risk stratification

Specific Drug Selection

Choose either:

• ACE inhibitor (e.g., lisinopril, enalapril, ramipril)
• ARB (e.g., losartan, telmisartan, irbesartan)

Recent real-world data from Singapore suggests ACE inhibitors may have a slight edge over ARBs in delaying CKD progression (HR 1.14 for ARBs vs ACEIs) 3, though both are acceptable first-line agents.

Target Blood Pressure

Aim for <130/80 mmHg 1, 2. In Asian populations with CKD, this intensive control is particularly important given:

• Higher prevalence of non-dipping BP patterns due to high dietary salt intake 4
• Stroke being more closely related to BP in Asian populations than coronary events 4

Implementation Protocol

Week 0-2:

• Start RAS inhibitor at standard dose
• Educate on dietary sodium restriction (crucial in Asian populations)
• Check BP, serum creatinine, and potassium within 2-4 weeks 1

Week 2-4 Monitoring:

• Accept up to 30% rise in creatinine (this is hemodynamic and expected) 1
• Stop or reduce dose if creatinine rises >30% within 4 weeks 1
• Manage hyperkalemia with dietary modification, diuretics, or potassium binders rather than stopping RAS inhibitor 1

Dose Titration:

• Use the highest approved tolerated dose to achieve proven benefits from clinical trials 1
• If BP target not achieved, add calcium channel blocker or thiazide-type diuretic as second agent 1, 4

Common Pitfalls to Avoid

1. Don't stop RAS inhibitor prematurely for mild creatinine elevation (<30% increase) - this is expected and beneficial long-term 1

2. Don't use dual RAS blockade (ACE inhibitor + ARB, or either with direct renin inhibitor) - this is contraindicated and harmful 1

3. Don't delay treatment waiting for albuminuria results - given her eGFR <60, RAS inhibition is appropriate regardless 1

4. Don't use mineralocorticoid receptor antagonists as first-line - reserve for refractory hypertension, as hyperkalemia risk is substantial at this eGFR 1

Special Consideration for Young Asian Female

At age 30, assess pregnancy plans immediately. If pregnancy is possible:

• Counsel on teratogenic risks of RAS inhibitors
• Ensure reliable contraception or consider alternative agents (calcium channel blocker, methyldopa)
• Document this discussion

The combination of young age and CKD stage G3a warrants investigation for secondary causes of hypertension (renovascular disease, primary aldosteronism, autoimmune kidney disease) alongside treatment initiation.